Through the collaboration, ADC Therapeutics has been granted nonexclusive rights for two additional Synaffix antibody-drug conjugate programs -- five in total since October 2016. ADC Therapeutics has gained access to the newest Synaffix technology, including the proprietary GlycoConnect platform that enables stable attachment of a single drug per antibody.
ADC Therapeutics is responsible for the research, development, manufacturing, and commercialization of any resulting products from the collaboration.
Synaffix is eligible to receive upfront, milestone, and royalty payments associated with each program. Further financial details were not disclosed.
Copyright © 2020 scienceboard.net